Overview of Nicotine Withdrawal and Negative Reinforcement (Preclinical)

Negative Affective States and Cognitive Impairments in Nicotine Dependence

Volumn , Issue , 2017, Pages 1-20

  George, O ^a   Koob, G F ^a,b,c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Abstinence; Addiction; Animal model; Dependence; Escalation; Minipump; Self administration; Smoke; Tobacco; Vapor

Indexed keywords

EID: 85017456971     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-802574-1.00001-6     Document Type: Chapter

References (129)

1. Agaku I.T., King B.A., Dube S.R. Current cigarette smoking among adults: United States, 2005-2012. Morbidity and Mortality Weekly Report 2014, 63:29-34.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Press, Washington, DC. 4th ed., text revision.
3. Azam L., Winzer-Serhan U.H., Chen Y., Leslie F.M. Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. Journal of Comparative Neurology 2002, 444:260-274.
4. Balfour D.J. Nicotine and the tobacco smoking habit. Nicotine and the tobacco smoking habit. Series title: International encyclopedia of pharmacology and therapeutics 1984, Vol. 114:61-74. Pergamon Press, New York. D.J.K. Balfour (Ed.).
5. Benowitz N.L. Drug therapy: pharmacologic aspects of cigarette smoking and nicotine addiction. The New England Journal of Medicine 1988, 319:1318-1330.
6. Benowitz N.L. Pharmacology of nicotine: addiction and therapeutics. Annual Review of Pharmacology and Toxicology 1996, 36:597-613.
7. Benowitz N.L., Jacob P. Nicotine and carbon monoxide intake from high- and low-yield cigarettes. Clinical Pharmacology and Therapeutics 1984, 36:265-270.
8. Benowitz N.L., Porchet H., Sheiner L., Jacob P. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clinical Pharmacology and Therapeutics 1988, 44:23-28.
9. Benwell M.E., Balfour D.J. Effects of nicotine administration and its withdrawal on plasma corticosterone and brain 5-hydroxyindoles. Psychopharmacology 1979, 63:7-11.
10. Bruijnzeel A.W., Gold M.S. The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. Brain Research Reviews 2005, 49:505-528.
11. Carboni E., Acquas E., Leone P., Di Chiara G. 5HT3 receptor antagonists block morphine- and nicotine- but not amphetamine-induced reward. Psychopharmacology 1989, 97:175-178.
12. Clarke P.B.S., Pert A. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Research 1985, 348:355-358.
13. Cohen A., George O. Animal models of nicotine exposure: relevance to second-hand smoking, electronic cigarette use, and compulsive smoking. Frontiers in Psychiatry 2013, 4:41.
14. Cohen A., Koob G.F., George O. Robust escalation of nicotine intake with extended access to nicotine self-administration and intermittent periods of abstinence. Neuropsychopharmacology 2012, 37:2153-2160.
15. 1 receptor dependent increase in anxiety-like behavior and hyperalgesia in rats. Addiction Biology 2015, 20:56-68.
16. Corrigall W.A. Nicotine self-administration in animals as a dependence model. Nicotine and Tobacco Research 1999, 1:11-20.
17. Corrigall W.A., Coen K.M. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology 1989, 99:473-478.
18. Corrigall W.A., Coen K.M. Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology 1991, 104:171-176.
19. Corrigall W.A., Coen K.M., Adamson K.L. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Research 1994, 653:278-284.
20. Corrigall W.A., Coen K.M., Adamson K.L., Chow B.L., Zhang J. Response of nicotine self-administration in the rat to manipulations of mu-opioid and γ-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology 2000, 149:107-114.
21. Corrigall W.A., Coen K.M., Zhang J., Adamson K.L. GABA mechanisms in the pedunculopontine tegmental nucleus influence particular aspects of nicotine self-administration selectively in the rat. Psychopharmacology 2001, 158:190-197.
22. Corrigall W.A., Franklin K.B.J., Coen K.M., Clarke P.B.S. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 1992, 107:285-289.
23. Davis J.A., Kenney J.W., Gould T.J. Hippocampal alpha4beta2 nicotinic acetylcholine receptor involvement in the enhancing effect of acute nicotine on contextual fear conditioning. The Journal of Neuroscience 2007, 27:10870-10877.
24. Dewey S.L., Brodie J.D., Gerasimov M., Horan B., Gardner E.L., Ashby C.R. A pharmacologic strategy for the treatment of nicotine addiction. Synapse 1999, 31:76-86.
25. Donny E.C., Caggiula A.R., Knopf S., Brown C. Nicotine self-administration in rats. Psychopharmacology 1995, 122:390-394.
26. Enrico P., Sirca D., Mereu M., Peana A.T., Mercante B., Diana M. Acute restraint stress prevents nicotine-induced mesolimbic dopaminergic activation via a corticosterone-mediated mechanism: a microdialysis study in the rat. Drug and Alcohol Dependence 2013, 127:8-14.
27. Epping-Jordan M.P., Watkins S.S., Koob G.F., Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 1998, 393:76-79.
28. Faraday M.M., Blakeman K.H., Grunberg N.E. Strain and sex alter effects of stress and nicotine on feeding, body weight, and HPA axis hormones. Pharmacology, Biochemistry, and Behavior 2005, 80:577-589.
29. 1 receptors as a novel target for the treatment of nicotine addiction. Neuropsychopharmacology 2010, 35:1751-1760. [erratum: 35(9): 2006].
30. Fowler C.D., Kenny P.J. Nicotine aversion: neurobiological mechanisms and relevance to tobacco dependence vulnerability. Neuropharmacology 2014, 76(Pt B):533-544.
31. Fowler C.D., Lu Q., Johnson P.M., Marks M.J., Kenny P.J. Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature 2011, 471:597-601.
32. Fu Y., Matta S.G., Brower V.G., Sharp B.M. Norepinephrine secretion in the hypothalamic paraventricular nucleus of rats during unlimited access to self-administered nicotine: an in vivo microdialysis study. The Journal of Neuroscience 2001, 21:8979-8989.
33. Fu Y., Matta S.G., Kane V.B., Sharp B.M. Norepinephrine release in amygdala of rats during chronic nicotine self-administration: an in vivo microdialysis study. Neuropharmacology 2003, 45:514-523.
34. 1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. Proceedings of the National Academy of Sciences of the USA 2007, 104:17198-17203.
35. George O., Grieder T.E., Cole M., Koob G.F. Exposure to chronic intermittent nicotine vapor induces nicotine dependence. Pharmacology Biochemistry and Behavior 2010, 96:104-107.
36. Ghozland S., Zorrilla E., Parsons L.H., Koob G.F. Mecamylamine increases extracellular CRF levels in the central nucleus of the amygdala or nicotine-dependent rats. Society for Neuroscience 2004, 30. abstract# 708.8.
37. Gilpin N.W., Whitaker A.M., Baynes B., Abdel A.Y., Weil M.T., George O. Nicotine vapor inhalation escalates nicotine self-administration. Addiction Biology 2014, 19:587-592.
38. Goldberg S.R., Henningfield J.E. Reinforcing effects of nicotine in humans and experimental animals responding under intermittent schedules of i.v. drug injection. Pharmacology, Biochemistry, and Behavior 1988, 30:227-234.
39. Goldberg S.R., Spealman R.D. Maintenance and suppression of behavior by intravenous nicotine injections in squirrel monkeys. Federation Proceedings 1982, 41:216-220.
40. Goldberg S.R., Spealman R.D. Suppression of behavior by intravenous injections of nicotine or by electric shocks in squirrel monkeys: effects of chlordiazepoxide and mecamylamine. The Journal of Pharmacology and Experimental Therapeutics 1983, 224:334-340.
41. Goldberg S.R., Spealman R.D., Goldberg D.M. Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 1981, 214:573-575.
42. Goldberg S.R., Spealman R.D., Risner M.E., Henningfield J.E. Control of behavior by intravenous nicotine injections in laboratory animals. Pharmacology, Biochemistry, and Behavior 1983, 19:1011-1020.
43. Goniewicz M.L., Hajek P., McRobbie H. Nicotine content of electronic cigarettes, its release in vapour and its consistency across batches: regulatory implications. Addiction 2014, 109:500-507.
44. Goodwin A.K., Hiranita T., Paule M.G. The reinforcing effects of nicotine in humans and nonhuman primates: a review of intravenous self-administration evidence and future directions for research. Nicotine and Tobacco Research 2015, 17:1297-1310.
45. Gould T.J., Leach P.T. Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning. Neurobiology of Learning and Memory 2014, 107:108-132.
46. Grieder T.E., George O., Tan H., George S.R., Le Foll B., Laviolette S.R., et al. Phasic D1 and tonic D2 dopamine receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal. Proceedings of the National Academy of Sciences of the USA 2012, 109:3101-3106.
47. Grieder T.E., Herman M.A., Contet C., Tan L.A., Vargas-Perez H., Cohen A., et al. VTA CRF neurons mediate the aversive effects of nicotine withdrawal and promote intake escalation. Nature Neuroscience 2014, 17:1751-1758.
48. Guillem K., Vouillac C., Azar M.R., Parsons L.H., Koob G.F., Cador M., et al. Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. The Journal of Neuroscience 2005, 25:8593-8600.
49. Henningfield J.E., Miyasato K., Jasinski D.R. Cigarette smokers self-administer intravenous nicotine. Pharmacology, Biochemistry, and Behavior 1983, 19:887-890.
50. Hildebrand B.E., Nomikos G.G., Bondjers C., Nisell M., Svensson T.H. Behavioral manifestations of the nicotine abstinence syndrome in the rat: peripheral versus central mechanisms. Psychopharmacology 1997, 129:348-356.
51. Hildebrand B.E., Nomikos G.G., Hertel P., Schilstrom B., Svensson T.H. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Research 1998, 779:214-225.
52. Hildebrand B.E., Panagis G., Svensson T.H., Nomikos G.G. Behavioral and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: role of nicotinic receptors in the ventral tegmental area. Neuropsychopharmacology 1999, 21:560-574.
53. Houdi A.A., Pierzchala K., Marson L., Palkovits M., Van Loon G.R. Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides 1991, 12:161-166.
54. Hughes J.R., Gust S.W., Skoog K., Keenan R.M., Fenwick J.W. Symptoms of tobacco withdrawal: a replication and extension. Archives of General Psychiatry 1991, 48:52-59.
55. Hughes J.R., Hatsukami D.K., Pickens R.W., Krahn D., Malin S., Luknic A. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology 1984, 83:82-87.
56. Isaac P.F., Rand M.J. Cigarette smoking and plasma levels of nicotine. Nature 1972, 236:308-310.
57. Kaye S., Gilsenan J., Young J.T., Carruthers S., Allsop S., Degenhardt L., et al. Risk behaviours among substance use disorder treatment seekers with and without adult ADHD symptoms. Drug and Alcohol Dependence 2014, 144:70-77.
58. Koffarnus M.N., Winger G. Individual differences in the reinforcing and punishing effects of nicotine in rhesus monkeys. Psychopharmacology 2015, 232:2393-2403.
59. Koob G.F. Corticotropin-releasing factor, norepinephrine and stress. Biological Psychiatry 1999, 46:1167-1180.
60. Koob G.F., Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science 1988, 242:715-723.
61. Koob G.F., Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997, 278:52-58.
62. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001, 24:97-129.
63. Koob G.F., Le Moal M. Plasticity of reward neurocircuitry and the "dark side" of drug addiction. Nature Neuroscience 2005, 8:1442-1444.
64. Koob G.F., Le Moal M. Neurobiology of addiction 2006, Academic Press, London.
65. Koob G.F., Le Moal M. Addiction and the brain antireward system. Annual Review of Psychology 2008, 59:29-53.
66. Koob G.F., Markou A., Weiss F., Schulteis G. Opponent process and drug dependence: neurobiological mechanisms. Seminars in Neuroscience 1993, 5:351-358.
67. Koob G.F., Sanna P.P., Bloom F.E. Neuroscience of addiction. Neuron 1998, 21:467-476.
68. LeSage M.G., Keyler D.E., Collins G., Pentel P.R. Effects of continuous nicotine infusion on nicotine self-administration in rats: relationship between continuously infused and self-administered nicotine doses and serum concentrations. Psychopharmacology 2003, 170:278-286.
69. LeSage M.G., Keyler D.E., Shoeman D., Raphael D., Collins G., Pentel P.R. Continuous nicotine infusion reduces nicotine self-administration in rats with 23-h/day access to nicotine. Pharmacology Biochemistry and Behavior 2002, 72:279-289.
70. Lindstrom J. Nicotinic acetylcholine receptors in health and disease. Molecular Neurobiology 1997, 15:193-222.
71. Madden G.J., Bickel W.K. Abstinence and price effects on demand for cigarettes: a behavioral-economic analysis. Addiction 1999, 94:577-588.
72. Malin D.H., Lake J.R., Carter V.A., Cunningham J.S., Hebert K.M., Conrad D.L., et al. The nicotine antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology 1994, 115:180-184.
73. Malin D.H., Lake J.R., Carter V.A., Cunningham J.S., Wilson O.B. Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology 1993, 112:339-342.
74. Malin D.H., Lake J.R., Newlin-Maultsby P., Roberts L.K., Lanier J.G., Carter V.A., et al. Rodent model of nicotine abstinence syndrome. Pharmacology, Biochemistry, and Behavior 1992, 43:779-784.
75. Markou A., Kosten T.R., Koob G.F. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 1998, 18:135-174.
76. Maskos U., Molles B.E., Pons S., Besson M., Guiard B.P., Guilloux J.P., et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 2005, 436:103-107.
77. Matta S.G., Beyer H.S., McAllen K.M., Sharp B.M. Nicotine elevates rat plasma ACTH by a central mechanism. The Journal of Pharmacology and Experimental Therapeutics 1987, 243:217-226.
78. Matta S.G., Fu Y., Valentine J.D., Sharp B.M. Response of the hypothalamo-pituitary-adrenal axis to nicotine. Psychoneuroendocrinology 1998, 23:103-113.
79. Matta S.G., Valentine J.D., Sharp B.M. Nicotinic activation of CRH neurons in extrahypothalamic regions of the rat brain. Endocrine 1997, 7:245-253.
80. McGehee D.S., Heath M.J., Gelber S., Devay P., Role L.W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 1995, 269:1692-1696.
81. Mendelson J.H., Sholar M.B., Goletiani N., Siegel A.J., Mello N.K. Effects of low- and high-nicotine cigarette smoking on mood states and the HPA axis in men. Neuropsychopharmacology 2005, 30:1751-1763.
82. Morel C., Fattore L., Pons S., Hay Y.A., Marti F., Lambolez B., et al. Nicotine consumption is regulated by a human polymorphism in dopamine neurons. Molecular Psychiatry 2014, 19:930-936.
83. Nil R., Woodson P.P., Battig K. Effects of smoking deprivation on smoking behavior and heart rate response in high and low CO absorbing smokers. Psychopharmacology 1987, 92:465-469.
84. Nisell M., Marcus M., Nomikos G.G., Svensson T.H. Differential effects of acute and chronic nicotine on dopamine output in the core and shell of the rat nucleus accumbens. Journal of Neural Transmission 1997, 104:1-10.
85. Nisell M., Nomikos G.G., Svensson T.H. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 1994, 16:36-44.
86. Nomikos G.G., Hildebrand B.E., Panagis G., Svensson T.H. Nicotine withdrawal in the rat: role of α7 nicotinic receptors in the ventral tegmental area. Neuroreport 1999, 10:697-702.
87. Oakman S.A., Faris P.L., Kerr P.E., Cozzari C., Hartman B.K. Distribution of pontomesencephalic cholinergic neurons projecting to substantia nigra differs significantly from those projecting to ventral tegmental area. The Journal of Neuroscience 1995, 15:5859-5869.
88. Okada S., Shimizu T., Yokotani K. Extrahypothalamic corticotropin-releasing hormone mediates (-)-nicotine-induced elevation of plasma corticosterone in rats. European Journal of Pharmacology 2003, 473:217-223.
89. Orejarena M.J., Herrera-Solis A., Pons S., Maskos U., Maldonado R., Robledo P. Selective re-expression of β2 nicotinic acetylcholine receptor subunits in the ventral tegmental area of the mouse restores intravenous nicotine self-administration. Neuropharmacology 2012, 63:235-241.
90. O'Dell L.E., Bruijnzeel A.W., Smith R.T., Parsons L.H., Merves M.L., Goldberger B.A., et al. Diminished nicotine withdrawal in adolescent rats: implications for vulnerability to addiction. Psychopharmacology 2006, 186:612-619.
91. O'Dell L.E., Chen S.A., Smith R.T., Specio S.E., Balster R.L., Paterson N.E., et al. Extended access to nicotine self-administration leads to dependence: circadian measures, withdrawal measures, and extinction behavior in rats. The Journal of Pharmacology and Experimental Therapeutics 2007, 320:180-193.
92. Palazzolo D.L. Electronic cigarettes and vaping: a new challenge in clinical medicine and public health: a literature review. Frontiers in Public Health 2013, 1:56.
93. Panagis G., Hildebrand B.E., Svensson T.H., Nomikos G.G. Selective c-fos induction and decreased dopamine release in the central nucleus of amygdala in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Synapse 2000, 35:15-25.
94. Pandey S.C., Roy A., Xu T., Mittal N. Effects of protracted nicotine exposure and withdrawal on the expression and phosphorylation of the CREB gene transcription factor in rat brain. Journal of Neurochemistry 2001, 77:943-952.
95. Panin F., Lintas A., Diana M. Nicotine-induced increase of dopaminergic mesoaccumbal neuron activity is prevented by acute restraint stress: in vivo electrophysiology in rats. European Neuropsychopharmacology 2014, 24:1175-1180.
96. Paterson N.E., Markou A. Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats. Psychopharmacology 2004, 173:64-72.
97. Pomerleau O.F., Pomerleau C.S. Neuroregulators and the reinforcement of smoking: towards a biobehavioral explanation. Neuroscience and Biobehavioral Reviews 1984, 8:503-513.
98. Pomerleau C.S., Pomerleau O.F. Euphoriant effects of nicotine in smokers. Psychopharmacology 1992, 108:460-465.
99. Pons S., Fattore L., Cossu G., Tolu S., Porcu E., McIntosh J.M., et al. Crucial role of α4 and α6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. The Journal of Neuroscience 2008, 28:12318-12327.
100. Pontieri F.E., Passarelli F., Calo L., Caronti B. Functional correlates of nicotine administration: similarity with drugs of abuse. Journal of Molecular Medicine 1998, 76:193-201.
101. Pontieri F.E., Tanda G., Orzi F., Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996, 382:255-257.
102. Risner M.E., Goldberg S.R. A comparison of nicotine and cocaine self-administration in the dog: fixed-ratio and progressive-ratio schedules of intravenous drug infusion. The Journal of Pharmacology and Experimental Therapeutics 1983, 224:319-326.
103. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Research Reviews 1993, 18:247-291.
104. Rose J.E., Corrigall W.A. Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology 1997, 130:28-40.
105. Rusted J.M., Mackee A., Williams R., Willner P. Deprivation state but not nicotine content of the cigarette affects responding by smokers on a progressive ratio task. Psychopharmacology 1998, 140:411-417.
106. Salin-Pascual R.J., Moro-Lopez M.L., Gonzalez-Sanchez H., Blanco-Centurion C. Changes in sleep after acute and repeated administration of nicotine in the rat. Psychopharmacology 1999, 145:133-138.
107. Schilstrom B., Nomikos G.G., Nisell M., Hertel P., Svensson T.H. N-methyl-d-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 1998, 82:781-789.
108. Semba J., Wakuta M., Maeda J., Suhara T. Nicotine withdrawal induces subsensitivity of hypothalamic-pituitary-adrenal axis to stress in rats: implications for precipitation of depression during smoking cessation. Psychoneuroendocrinology 2004, 29:215-226.
109. Shahan T.A., Bickel W.K., Badger G.J., Giordano L.A. Sensitivity of nicotine-containing and de-nicotinized cigarette consumption to alternative non-drug reinforcement: a behavioral economic analysis. Behavioural Pharmacology 2001, 12:277-284.
110. Shahan T.A., Bickel W.K., Madden G.J., Badger G.J. Comparing the reinforcing efficacy of nicotine containing and de-nicotinized cigarettes: a behavioral economic analysis. Psychopharmacology 1999, 147:210-216.
111. Sharp B.M., Matta S.G. Detection by in vivo microdialysis of nicotine-induced norepinephrine secretion from the hypothalamic paraventricular nucleus of freely moving rats: dose-dependency and desensitization. Endocrinology 1993, 133:11-19.
112. Shiffman S.M., Jarvik M.E. Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology 1976, 50:35-39.
113. Slawecki C.J., Thorsell A.K., Khoury A.E., Mathe A.A., Ehlers C.L. Increased CRF-like and NPY-like immunoreactivity in adult rats exposed to nicotine during adolescence: relation to anxiety-like and depressive-like behavior. Neuropeptides 2005, 39:369-377.
114. Stinus L., Cador M., Zorrilla E.P., Koob G.F. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 2005, 30:90-98.
115. Stolerman I.P. Behavioural pharmacology of nicotine: multiple mechanisms. British Journal of Addiction 1991, 86:533-536.
116. Stolerman I.P., Jarvis M.J. The scientific case that nicotine is addictive. Psychopharmacology 1995, 117:2-10. (discussion 14-20).
117. Swanson L.W., Simmons D.M., Whiting P.J., Lindstrom J. Immunohistochemical localization of neuronal nicotinic receptors in the rodent central nervous system. The Journal of Neuroscience 1987, 7:3334-3342.
118. Tago H., McGeer P.L., McGeer E.G., Akiyama H., Hersh L.B. Distribution of choline acetyltransferase immunopositive structures in the rat brainstem. Brain Research 1989, 495:271-297.
119. Tejeda H.A., Natividad L.A., Orfila J.E., Torres O.V., O'Dell L.E. Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner. Psychopharmacology 2012, 224:289-301.
120. Tolu S., Eddine R., Marti F., David V., Graupner M., Pons S., et al. Co-activation of VTA DA and GABA neurons mediates nicotine reinforcement. Molecular Psychiatry 2013, 18:382-393.
121. 9-41, reverses nicotine-induced conditioned, but not unconditioned, anxiety. Psychopharmacology 2003, 167:251-256.
122. Valentine J.D., Hokanson J.S., Matta S.G., Sharp B.M. Self-administration in rats allowed unlimited access to nicotine. Psychopharmacology 1997, 133:300-304.
123. Vendruscolo L.F., Barbier E., Schlosburg J.E., Misra K.K., Whitfield T., Logrip M.L., et al. Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats. The Journal of Neuroscience 2012, 32:7563-7571.
124. Watkins S.S., Epping-Jordan M.P., Koob G.F., Markou A. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacology, Biochemistry, and Behavior 1999, 62:743-751.
125. Watkins S.S., Koob G.F., Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine and Tobacco Research 2000, 2:19-37.
126. Watkins S.S., Stinus L., Koob G.F., Markou A. Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. The Journal of Pharmacology and Experimental Therapeutics 2000, 292:1053-1064.
127. Young J.W., Finlayson K., Spratt C., Marston H.M., Crawford N., Kelly J.S., et al. Nicotine improves sustained attention in mice: evidence for involvement of the α7 nicotinic acetylcholine receptor. Neuropsychopharmacology 2004, 29:891-900.
128. Young J.W., Meves J.M., Geyer M.A. Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behavioural Brain Research 2013, 240:119-133.
129. Zhao-Shea R., DeGroot S.R., Liu L., Vallaster M., Pang X., Su Q., et al. Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during nicotine withdrawal. Nature Communications 2015, 6:6770.